success
lentivir
vector
cure
fatal
genet
acquir
diseas
open
new
era
human
gene
therapi
howev
variabl
efficaci
safeti
therapeut
approach
report
human
patient
consequ
lentiviralvectorbas
gene
therapi
limit
incur
human
diseas
littl
understand
underli
caus
advers
effect
poor
efficaci
assess
role
host
genet
variat
efficaci
gene
therapi
character
lentiviralvector
gene
therapi
within
set
collabor
cross
mous
strain
lentivir
vector
carri
firefli
luciferas
cdna
control
liverspecif
promot
administ
femal
mice
totalbodi
hepat
luciferas
express
period
monitor
week
postvector
administr
vector
copi
number
per
diploid
genom
mous
liver
spleen
determin
end
studi
identifi
major
strainspecif
contribut
overal
success
transduct
vector
biodistribut
maximum
luciferas
express
kinet
luciferas
express
throughout
studi
result
highlight
import
genet
variat
genetherapeut
efficaci
provid
new
model
rigor
assess
gene
therapi
approach
suggest
redesign
preclin
studi
genetherapi
methodolog
might
appropri
similar
viral
vector
lentivir
vector
design
support
singl
round
transduct
process
compris
multipl
step
depend
uniqu
host
factor
also
restrict
retroviralspecif
restrict
factor
well
host
innat
adopt
immun
respons
process
singleround
vector
transduct
includ
vector
attach
relev
envelop
receptor
host
cell
membran
uncoat
revers
transcript
nuclear
import
integr
transgen
express
notwithstand
central
role
host
factor
process
viral
infect
current
preclin
studi
determin
efficaci
safeti
viral
vector
usual
base
rodent
studi
compris
larg
cohort
genet
ident
anim
follow
larg
anim
eg
primat
studi
use
rel
small
number
outbr
anim
consequ
sever
clinic
trial
use
variou
viral
vector
result
major
advers
effect
could
predict
cognat
preclin
studi
furthermor
limit
number
individu
elig
gene
therapi
clinic
trial
fact
individu
alreadi
signific
health
issu
limit
abil
meaning
use
outcom
determin
host
genet
variant
put
individu
higher
risk
advers
effect
render
like
benefit
gene
therapi
protocol
advanc
lentivir
vector
system
follow
success
human
clinic
trial
either
gene
replac
immunotherapi
either
fatal
monogen
diseas
cancer
respect
notwithstand
overal
success
clinic
trial
signific
variat
observ
efficaci
safeti
trial
well
within
patient
specif
trial
notabl
among
vectortr
patient
one
patient
receiv
hematopoieticstemcelldirect
gene
replac
therapi
bthalassemia
demonstr
vectorinduc
insert
mutagenesi
variabl
efficaci
safeti
hivbas
vector
clinic
trial
line
earlier
preclin
studi
demonstr
signific
strainspecif
differ
vector
efficaci
safeti
howev
low
number
anim
inbr
strain
employ
studi
limit
abil
assess
impact
specif
genet
differ
phenomena
inde
given
grow
bodi
evid
host
genet
variant
impact
antivir
respons
well
overal
gene
regul
within
individu
abl
accur
assess
quantifi
genet
variant
effect
gene
therapi
approach
critic
advanc
field
relev
studi
vivo
mammalian
respons
collabor
cross
cc
panel
recombin
inbr
mous
strain
exist
genet
refer
panel
inbr
mous
strain
deriv
set
eight
founder
strain
includ
five
classic
laboratori
mous
strain
three
wildderiv
strain
togeth
founder
repres
three
mu
musculu
subspeci
contain
million
snp
four
million
insert
delet
segreg
high
minor
allel
frequenc
across
collabor
cross
furthermor
across
grow
number
studi
variant
within
collabor
cross
relat
divers
outbr
shown
impact
varieti
antivir
generegulatori
process
specif
number
studi
identifi
host
genet
variant
impact
innat
antivir
respons
also
aberr
adapt
immun
respons
pathogen
given
relianc
gene
therapeut
efficaci
assess
one
two
classic
inbr
strain
eg
balbc
divers
popul
collabor
cross
provid
use
tool
assess
impact
host
genet
variat
potenti
efficaci
vectorbas
gene
therapeut
approach
potenti
offtarget
effect
ultim
identifi
polymorph
genom
featur
drive
respons
order
assess
impact
host
genet
variat
efficaci
well
safeti
lentivirusbas
gene
therapeut
regimen
transduc
collabor
cross
strain
well
mice
livertarget
lentiviru
vector
express
luciferas
found
evid
strong
effect
host
genet
variant
abil
lentivir
vector
success
ferri
genet
cargo
host
cell
nuclei
maintain
hepat
transgen
express
studi
highlight
critic
need
assess
safeti
efficaci
gene
therapeut
approach
across
rang
genet
variabl
background
evalu
effect
host
genet
variat
lentiviralvectorbas
gene
deliveri
vivo
administ
lentivir
vector
via
intraperiton
inject
femal
mice
collabor
cross
strain
well
prototyp
model
n
collabor
cross
strain
chosen
base
avail
suffici
size
cohort
within
age
window
time
studi
also
select
suffici
unbiasedli
sampl
genet
variat
present
within
entir
collabor
cross
popul
eg
strain
repres
genet
bias
subset
strain
one
mous
die
inject
two
mice
exclud
studi
post
hoc
observ
failur
deliv
vector
anim
vector
vsvg
pseudotyp
express
firefli
luciferas
control
liverspecif
promot
human
haat
luciferas
express
liver
whole
mous
bodi
quantifi
vivo
imag
week
figur
week
postinfect
identifi
almost
differ
mous
strain
totalbodi
luciferas
log
figur
vivo
luciferas
express
across
mous
strain
follow
introduct
luciferaseexpress
lentiviru
femal
mice
sever
strain
follow
week
regular
assess
week
postlentivir
vector
administr
vivo
luciferas
express
pscm
sr
color
scale
set
standard
laboratori
strain
compar
highli
express
strain
well
lownonexpress
strain
rang
photonss
classic
strain
intermedi
luciferas
level
log
mean
sd
time
point
rel
collabor
cross
strain
figur
tabl
differ
collabor
cross
strain
total
luciferas
express
highli
signific
f
p
order
better
ascertain
percentag
phenotyp
variat
popul
attribut
genet
differ
strain
estim
broadsens
herit
detail
see
materi
method
conserv
coeffici
genet
determin
cgd
wherea
liber
interclass
correl
icc
look
across
time
cours
identifi
signific
effect
strain
f
p
time
f
p
well
interact
two
factor
f
p
wholebodi
luciferas
express
studi
respons
seen
clearli
figur
tabl
overal
modest
increas
luciferas
express
seen
experi
howev
strain
eg
geniunc
show
stabl
luciferas
express
throughout
experi
one
strain
show
reduc
luciferas
express
throughout
studi
ideal
gene
therapeut
product
specif
target
given
tissu
abl
assess
liverspecif
express
luciferas
across
set
mous
strain
kinet
time
cours
gener
total
liverspecif
luciferas
level
highli
correl
r
figur
throughout
studi
therefor
analysi
data
tightli
mirror
respons
seen
total
luciferas
level
liver
found
evid
strain
effect
f
p
also
strainbytim
point
interact
f
p
howev
although
identifi
moder
effect
time
point
total
luciferas
level
identifi
effect
time
point
f
p
liverspecif
luciferas
express
furthermor
week
found
total
luciferas
liverspecif
luciferas
express
herit
high
rang
cgd
icc
examin
data
tabl
show
gener
liverspecif
level
stabl
studi
strain
show
modest
chang
effect
given
line
evid
especi
discord
tempor
respons
total
liverspecif
luciferas
final
ask
whether
overal
proport
luciferas
express
within
individu
host
genet
control
first
examin
correl
total
luciferas
express
fraction
luciferas
signal
come
liver
found
modest
correl
two
trait
r
figur
importantli
sampl
broad
rang
total
luciferas
express
photonss
could
still
exhibit
low
level
liverspecif
express
suggest
individu
anim
low
fraction
liverspecif
respons
low
total
level
eg
sampl
difficult
assess
incorrect
attribut
spillov
liver
therefor
assess
respons
chang
throughout
studi
expect
identifi
signific
strain
f
p
time
point
f
p
interact
factor
f
p
drive
fraction
luciferas
express
come
liver
herit
estim
week
rang
cgd
icc
exampl
maintain
consist
high
proport
total
luciferas
come
liver
similar
wherea
show
decreas
fraction
express
come
liver
time
note
show
increas
fraction
respons
come
liver
suggest
although
might
fluctuat
tissu
silenc
within
liver
strain
expans
luciferas
express
tissu
follow
revers
transcript
lentivir
vector
effici
import
genet
materi
host
cell
nuclei
serv
templat
transcript
relev
transgen
interest
success
gene
therapi
vector
requir
longterm
persist
vectortransduc
cell
follow
studi
termin
liver
spleen
tissu
collect
anim
qpcr
assay
perform
identifi
number
vector
copi
deliv
host
cell
nuclei
vector
copi
number
per
cell
vcn
liver
differ
log
min
max
mean
copiescel
figur
show
highest
level
vcn
within
liver
copiescel
collabor
cross
strain
show
lower
level
vcn
collabor
cross
strain
show
signific
differ
liver
vcn
f
p
herit
estim
suggest
cgd
icc
variat
vector
copiescel
liver
host
genet
control
level
vcn
within
spleen
strain
reduc
rel
liver
min
max
mean
copiescel
although
strong
correl
vector
copi
liver
vector
copi
spleen
r
show
rel
high
level
vector
copiesspleen
vector
copi
per
cell
contrast
liverspecif
vcn
mous
strain
highest
level
spleen
vcn
figur
liver
level
approxim
differ
highest
lowest
collabor
cross
strain
differ
statist
signific
f
p
spleen
level
vector
mainten
herit
cgd
icc
across
collabor
cross
strain
given
highli
signific
variat
total
liverspecif
luciferas
express
collect
mous
strain
sought
assess
extent
host
genet
differ
control
express
level
given
strainspecif
vcn
differ
effici
transgen
express
determin
rel
express
luciferas
week
within
liver
mous
rel
liver
vcn
found
vectorspecif
activ
mous
liver
f
p
impact
host
strain
figur
herit
analysi
show
cgd
icc
variat
vectorspecif
activ
liver
explain
host
genet
variat
util
second
analysi
assess
impact
host
genet
variat
luciferas
express
independ
host
genet
variat
impact
vector
copi
number
use
partial
ftest
assess
improv
fit
model
explain
luciferas
level
includ
strain
vector
copi
number
oppos
vector
copi
number
alon
found
strong
evid
liver
luciferas
express
host
factor
drive
express
f
p
although
evid
total
luciferas
express
signific
f
p
total
mice
within
studi
die
cours
experi
mortal
impact
seven
strain
tabl
experienc
highest
mortal
mice
sacrific
six
mice
four
strain
show
appear
macroscop
abnorm
includ
liver
spleen
tumor
patholog
analysi
suggest
common
lesion
type
age
anim
unlik
due
presenc
vectorrel
issu
figur
tabl
although
gene
therapi
approach
power
allevi
sever
congenit
condit
sever
aspect
viralvectordeliv
gene
therapeut
regimen
rais
caus
concern
specif
success
gene
therapi
requir
optim
respons
varieti
process
singl
deliveri
event
includ
limit
deliveri
viral
vector
specif
target
cell
effici
transfer
viral
genom
host
cell
nuclei
mainten
therapeut
level
transgen
express
without
caus
harm
advers
effect
ineffici
process
well
unforeseen
advers
effect
clinic
trial
greatest
impedi
broad
adopt
gene
therapi
mean
treat
nonfat
diseas
although
studi
suggest
host
genet
differ
play
role
gene
therapi
outcom
littl
research
role
host
genet
variat
play
efficaci
mainten
safeti
viralvectordriven
gene
therapeut
approach
sought
assess
magnitud
impact
host
genet
variat
could
gene
therapeut
efficaci
use
set
strain
collabor
cross
genet
refer
panel
found
host
genet
variat
impact
multipl
aspect
gene
therapi
respons
within
host
furthermor
respons
alway
correl
across
strain
eg
vcn
total
luciferas
express
one
wide
use
mous
strain
fact
refer
mous
genom
variou
mous
model
emul
human
diseas
establish
genet
background
includ
sever
line
mice
model
hemophilia
use
adenoviraland
aavbas
vector
gene
therapi
preclin
studi
hemophilia
b
field
et
al
mingozzi
et
al
demonstr
induct
immun
toler
longterm
therapeut
level
express
vectordeliv
human
factor
ix
readili
achiev
mice
compar
balbc
although
precis
assess
genet
contribut
within
studi
character
earlier
lentiviralvectorbas
preclin
studi
follenzi
et
al
show
superior
lentivir
vector
longterm
express
less
promin
adapt
immun
respons
vectordeliv
gfp
report
gene
human
factor
ix
mice
compar
fvbn
balbc
mice
surprisingli
mice
consid
permiss
model
lentiviralvectorbas
gene
deliveri
line
follenzi
studi
found
peak
luciferas
express
strain
higher
mani
collabor
cross
strain
studi
importantli
studi
two
collabor
cross
strain
geniunc
exhibit
equival
higher
level
transgen
express
strain
later
time
point
furthermor
studi
show
differ
peak
luciferas
express
across
strain
data
suggest
signific
differ
efficaci
gene
therapi
protocol
human
patient
anticip
sole
due
genet
differ
addit
peak
level
transgen
express
longterm
mainten
therapeut
level
vectordeliv
transgen
requir
characterist
vivo
gene
transfer
procedur
directli
affect
success
vivo
gene
therapi
protocol
earli
studi
zhang
et
al
associ
develop
humor
immun
respons
human
factor
ix
deliv
aavbas
vector
slow
kinet
vivo
transduct
studi
kinet
lentiviralvectormedi
luciferas
express
throughout
studi
differ
significantli
mous
strain
although
modest
increas
luciferas
express
strain
subset
strain
show
reduct
luciferas
express
throughout
studi
notabl
seen
strain
show
decreas
level
luciferas
express
throughout
studi
also
show
high
mortal
throughout
studi
overal
result
line
earlier
studi
show
stabl
longterm
express
luciferas
human
factor
ix
integr
lentivir
vector
immunecompet
mice
howev
earlier
lentiviralvectorbas
preclin
studi
report
dramat
reduct
transgen
express
week
postinject
phenomenon
allevi
transgenedepend
manner
inhibit
offtarget
transgen
express
antigen
present
cell
sever
mechan
contribut
reduct
vectordeliv
transgen
express
thu
limit
efficaci
safeti
gene
therapi
protocol
mechan
includ
adapt
wwwmoleculartherapyorg
immun
respons
direct
vectortransduc
cell
adapt
immun
respons
vectordeliv
gene
product
transgen
toxic
silenc
vector
express
cassett
previou
clinic
trial
studi
suggest
immun
respons
target
cell
lead
advers
effect
although
studi
abl
conclus
investig
whether
transgen
silenc
mortal
connect
result
immun
respons
data
suggest
host
genotypespecif
respons
lead
suboptim
advers
gene
therapeut
respons
vector
biodistribut
key
characterist
genedeliveri
system
lentivir
vector
biodistribut
control
effici
reversetranscrib
vector
genom
nuclear
import
express
variou
host
organ
follow
system
administr
abil
transduc
nondivid
cell
facilit
vivo
gene
deliveri
hallmark
lentivirus
lentivir
vector
system
surprisingli
date
effect
host
genet
variat
vector
biodistribut
character
abl
identifi
differ
success
vsvgpseudotyp
lentivir
vector
deliv
reversetranscrib
genom
desir
target
liver
bystand
spleen
tissu
express
vcn
collabor
cross
strain
assess
except
three
mous
strain
vcn
level
liver
tissu
remark
high
collabor
cross
mous
strain
exhibit
compar
level
vcn
liver
spleen
tissu
furthermor
strong
correl
across
anim
level
copi
tissu
find
line
earlier
report
pan
et
al
show
compar
vcn
level
liver
spleen
tissu
follow
intraven
administr
vsvgpseudotyp
lentivir
vector
balbc
mice
result
suggest
variant
host
factor
impact
efficaci
deliveri
mainten
cell
transform
vector
nuclear
import
vector
dna
prerequisit
vector
transcript
activ
directli
affect
biodistribut
transgen
express
howev
vector
design
host
factor
also
major
effect
transgen
express
vectortransduc
cell
studi
liverspecif
promot
haat
control
vectormedi
luciferas
express
inde
mous
strain
exhibit
predominantli
hepat
express
howev
sever
mous
strain
demonstr
rel
high
extrahepat
transgen
express
furthermor
earlier
studi
report
extrahepat
transgen
express
nonhepat
cell
line
vitro
extra
hepat
tissu
vivo
lentivir
vector
carri
liverspecif
promot
although
mechan
involv
phenomenon
complet
elucid
gener
attribut
enhanc
promot
effect
host
chromatin
liverspecif
promot
integr
lentivir
vector
addit
vcn
level
specif
activ
lentivir
vector
express
cassett
determin
total
transgen
activ
per
vector
genom
directli
affect
therapeut
efficaci
lentivir
vector
therapeut
agent
although
vectorspecif
activ
compar
across
collabor
cross
mous
strain
signific
high
specif
activ
exhibit
strain
furthermor
strikingli
prototyp
strain
show
much
modest
specif
activ
overal
luciferas
express
level
would
indic
highlight
need
assess
transduct
effici
well
transgen
express
consid
success
gene
therapi
phenomenon
attribut
singl
combin
strainspecif
transcript
posttransl
host
factor
enhanc
luciferas
activ
mous
strain
observ
highli
import
gene
therapi
field
strongli
suggest
therapeut
vector
load
patient
specif
approach
could
potenti
reduc
transgen
cytotox
one
hand
optim
overal
vector
genom
requir
achiev
therapeut
transgen
express
minim
advers
effect
hand
inde
insert
mutagenesi
major
biosafeti
inher
integr
vector
includ
lentivir
vector
previou
studi
found
evid
differenti
oncogen
potenti
identifi
mice
four
collabor
cross
strain
use
studi
tabl
macroscop
liver
abnorm
follow
termin
presenc
abnorm
appear
tie
lentivir
transduct
propens
develop
specif
cancer
type
known
genet
control
howev
indepth
futur
studi
robust
casecontrol
framework
requir
understand
potenti
exacerb
tumorigenesi
driven
lentivir
vector
well
assess
distribut
integr
oncogen
extent
host
genet
differ
directli
eg
integr
site
bias
indirectli
eg
epigenet
chromatin
differ
might
alter
demonstr
strong
effect
host
genet
variat
level
kinet
transgen
express
level
vcn
vectorspecif
activ
larger
number
collabor
cross
strain
facilit
identif
put
genet
loci
involv
strainspecif
characterist
vivo
lentivir
vector
gene
deliveri
avoid
genderspecif
effect
hepat
transduct
studi
premis
femal
mice
although
resourc
demand
addit
studi
compris
male
mice
need
identifi
genderspecif
effect
lentivir
vector
transduct
effici
anticip
use
collabor
cross
mous
system
vitro
set
would
elucid
molecular
mechan
host
genet
variat
affect
specif
step
life
cycl
howev
establish
abil
genet
identifi
host
factor
affect
efficaci
lentivir
vector
ferri
therapeut
genet
cargo
set
genet
diseas
model
challeng
lentivir
vector
harbor
firefli
luciferas
cdna
control
liverspecif
promot
haat
construct
use
describ
earlier
lentivir
vector
particl
packag
packag
cassett
dnrf
cell
use
threeplasmid
transient
transfect
previous
describ
vector
titer
determin
measur
capsid
concentr
use
elisa
previous
describ
vector
prep
test
absenc
replicationcompet
retroviru
describ
earlier
procedur
involv
anim
studi
perform
accord
guid
care
use
laboratori
anim
anim
studi
protocol
approv
univers
north
carolina
unc
institut
anim
care
usag
committe
mice
purchas
jackson
laboratori
unc
system
genet
core
facil
collabor
cross
strain
list
tabl
http
csbiounceduccstatusindexpi
runavailablelin
femal
mice
acquir
week
age
acclim
week
experiment
facil
femal
anim
n
intraperiton
inject
mg
gag
lentivir
vector
ml
phosphatebuff
solut
vivo
express
vectordeliv
firefli
luciferas
live
anim
determin
week
use
ivi
lumina
optic
imag
system
perkinelm
end
anim
intraperiton
inject
ml
mg
dluciferin
potassium
salt
reconstitut
phosphatebuff
solut
regi
technolog
imag
initi
min
dluciferin
inject
use
exposur
time
rel
light
count
obtain
chargecoupl
devic
ccd
camera
convert
physic
unit
surfac
radianc
ps
cm
sr
display
luminesc
radianc
mode
vivo
luciferas
activ
shown
studi
analyz
use
live
imag
softwar
perkinelm
report
total
flux
photon
measur
wholebodi
liverspecif
luciferas
activ
ident
region
interest
roi
measur
compris
either
whole
anim
bodi
exclud
head
tail
liver
respect
figur
luciferas
activ
respect
roi
anim
measur
describ
offliv
luciferas
activ
calcul
subtract
liverspecif
activ
wholebodi
luciferas
activ
end
experi
viral
copi
number
liver
spleen
tissu
determin
genom
dna
tissu
isol
use
blood
tissu
dneasi
kit
qiagen
accord
manufactur
instruct
rna
remov
use
rnase
fermenta
sampl
treat
dpni
new
england
biolab
total
vector
copi
number
sampl
quantifi
use
multiplex
qpcr
previous
describ
histopatholog
upon
tissu
harvest
liver
spleen
tissu
physic
abnorm
either
size
appear
observ
six
anim
four
strain
figur
tabl
sent
unc
anim
histopatholog
core
facil
histopatholog
examin
end
tissu
fix
neutral
buffer
formalin
embed
paraffin
section
microtom
stain
h
e
boardcertifi
veterinari
pathologist
analyz
h
estain
section
data
analyz
r
program
environ
cran
rprojectorg
broadsens
herit
assess
either
assess
vector
copi
studi
conclus
found
signific
strainspecif
differ
level
vector
copi
number
liver
spleen
b
time
point
c
also
determin
luciferas
level
per
vector
copi
liver
tissu
log
liverspecif
luciferaseliv
vcn
base
week
luciferas
level
found
strainspecif
level
specif
activ
point
one
anim
mice
red
collabor
cross
strain
blue
interclass
correl
coeffici
genet
determin
briefli
approach
use
anova
model
fit
assess
rel
ratio
mean
squar
explain
strain
differ
rel
mean
squar
error
data
approach
appli
scale
factor
rel
number
sampl
n
treatment
class
follow
interclass
correl
ms
strain
ms
error
ms
strain
n
ms
error
coeffici
genet
determin
strain
ms
error
strain
error
order
assess
signific
strain
differ
given
phenotyp
trait
data
normal
anova
use
identifi
signific
model
fit
assess
vector
strain
effect
drive
luciferas
express
use
partial
ftest
framework
data
studi
includ
calcul
luciferas
vector
copi
number
level
raw
imag
luciferas
calcul
avail
upon
request
collabor
cross
strain
use
within
studi
avail
system
genet
core
facil
http
csbio
unceduccstatusindexpi
runavailablelin
genotyp
file
haplotyp
reconstruct
avail
strain
site
tk
inventor
technolog
licens
unc
commerci
entiti
live
imag
display
luciferas
activ
taken
use
ivi
lumina
optic
imag
system
week
lentivir
vector
inject
imag
display
luminesc
surfac
radianc
pseccm
sr
color
scale
set
minimum
maximum
respect
except
lower
right
panel
level
luciferas
express
low
therefor
low
scale
use
alongsid
high
scale
liverspecif
luciferas
activ
mark
red
ellips
region
interest
roi
quantifi
data
analyz
use
live
imag
softwar
report
photonsec
note
imag
week
anim
switch
figur
patholog
assess
liver
spleen
h
e
stain
section
liver
spleen
tissu
six
anim
four
strain
liver
tissu
anim
liver
tissu
anim
liver
tissu
anim
spleen
tissu
anim
microscop
histopatholog
analysi
reveal
mononuclear
chronic
periport
infiltr
liver
tissu
mononuclear
chronic
periport
infiltr
liver
tissu
mononuclear
chronic
periport
infiltr
granuloma
central
hepatocellular
death
area
eosinophil
droplet
mononuclear
chronic
periport
infiltr
presum
granuloma
central
hepatocellular
death
mononuclear
neoplasialik
lymphoma
leukemia
like
mononuclear
neoplasia
lymphoma
spleen
tissu
section
imag
taken
use
magnif
display
scale
bar
micron
